Novavax WKN: A2PKMZ ISIN: US6700024010 Kürzel: NVAX Forum: Aktien Thema: Hauptdiskussion

Oh man @hsvsvs aus welchem Loch bist du jetzt gekrochen 🐀

Du und GoersenBuhu seid die größten Profis hier und in anderen Foren !!! 😂😂😂😂😂😂

Lass dich nicht von unserem leicht aggressiven griechischen Freund kyrios beeinflussen. Der hat mehrere Profile. Er schreibt mich grad unter Helena1 an.

ZDF Info Doku zum Thema Verschwörungstheorien und Covid 👌

😂

Ich arbeite u.a. mit ALG II Empfänger*innen. Soweit liegst Du richtig. Beim Bashing dieser Menschen bist Du hier immerhin Mainstream. 😉

Jeden Tag grün ist doch super kann so weiter gehen

@kyrios lass dich nicht ärgern von den Bashern. Da haben einige mehrere Accounts und treiben ihr Unwesen 🤦🏻‍♂️

Setze mich auf Ignore! 😂😂😂😂😂 Und gut ist! Du bist bestimmt ein Hartz IV Empfänger !😂😂😂 Soviel du in allen Foren schreibst ist nicht normal! 😂😂😂😂😂

Wenn du mich meinst sorry sollte nicht beleidigend sein.

59,20 Könnten wir uns auf einen gepflegteren Umgangston einigen. Sonst müsste ich dich auf Ignore setzen. 😉

Träume weiter. Du kannst froh sein wenn wir heute noch 2$ plus mitnehmen.

Dann lass uns mal sehen. Allein das MÜSSTE verrät den Fachmann. 😅

Novavax Investor Relations GAITHERSBURG, Md., Aug. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2022 financial results and operational highlights on Monday, August 8, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows: Conference call details: Date: Time: Dial-in number: Webcast: August 8, 2022 4:30 p.m. U.S. Eastern Daylight Time (EDT) (833) 974-2381 (Domestic) or (412) 317-5774 (International) ir.novavax.com/events Participants will be prompted to request to join the Novavax, Inc. call. To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast. Replay details: Date: Dial-in number: Passcode: Webcast: About Novavax Available starting at 7:30 p.m. EDT, August 8, 2022 until 11:59 p.m. U.S. EDT, August 15, 2022 (877) 344-7529 (Domestic) or (412) 317-0088 (International) 9237495 ir.novavax.com/events, until November 8, 2022 Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including the U.S., EC and the WHO. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. For more information, visit www.novavax.com and connect with us on LinkedIn. *NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season. Contacts: Investors Alex Delacroix | 240-268-2022 ir@novavax.com Media Ali Chartan or Giovanna Chandler | 202-709-5563 media@novavax.com SOURCE Novavax, Inc.